Clinical Trial Update: Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating a post-transplant immunomodulatory regimen (cyclophosphamide, abatacept, vedolizumab, and a calcineurin inhibitor) to prevent …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Biphenotypic Acute Leukemia
• Juvenile Myelomonocytic Leukemia
• Malignant Lymphoma
• Myeloblastic Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Abatacept (abatacept)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Calcineurin inhibitor (calcineurin inhibitor)
• Vedolizumab (vedolizumab)

Snippet

Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Conditions: Acute Lymphoblastic Leukemia, Myeloblastic Leukemia | Phase 3 | Status: ACTIVE_NOT_RECRUITING